The frequency of TIM-3/TIGIT double positive CD8+ T cells was 0.7% (interquartile range [IQR] 0.365%–1.07%) in the NPC group, higher than in the healthy control (0.33% [IQR 0.238%–0.502%]). This evidence concerns the gene CD8A and nasopharyngeal carcinoma.